Last $3.30 USD
Change Today -0.19 / -5.44%
Volume 12.0K
SNTI On Other Exchanges
Symbol
Exchange
OTC BB
OTC US
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

senesco technologies inc (SNTI) Snapshot

Open
$3.39
Previous Close
$3.49
Day High
$3.48
Day Low
$3.22
52 Week High
04/23/13 - $9.00
52 Week Low
07/23/13 - $1.90
Market Cap
16.6M
Average Volume 10 Days
14.8K
EPS TTM
$-2.26
Shares Outstanding
5.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SENESCO TECHNOLOGIES INC (SNTI)

Related News

No related news articles were found.

senesco technologies inc (SNTI) Related Businessweek News

No Related Businessweek News Found

senesco technologies inc (SNTI) Details

Senesco Technologies, Inc., a development stage biotechnology company, engages in the development of products and technologies for human therapeutic applications to treat cancer and inflammatory diseases. The company’s therapeutic candidate includes SNS01-T, which is in Phase Ib/IIa clinical study for the potential treatment of multiple myeloma, mantle cell lymphoma, and non-Hodgkin B-cell lymphomas. It also develops and licenses gene technologies to enhance the quality and productivity of fruits, flowers, vegetables, forestry species, agronomic crops, and biofuel feedstock crops through the control of cell death and growth in plants. The company was founded in 1964 and is based in Bridgewater, New Jersey.

11 Employees
Last Reported Date: 12/12/13
Founded in 1964

senesco technologies inc (SNTI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $273.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $178.0K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $67.5K
Vice President of Research & Development
Total Annual Compensation: $161.0K
Compensation as of Fiscal Year 2013.

senesco technologies inc (SNTI) Key Developments

Senesco Technologies Inc. Opens Two New Clinical Trial Sites and Initiates Treatment of the First Patient in South Africa

Senesco Technologies Inc. reported the opening of two new sites in the Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape Town. Treatment of the first patient in South Africa has been initiated in Senesco's Phase 1b/2a clinical study of its product candidate, SNS01-T. Pretoria East Hospital, a modern 358-bed facility, includes the Albert Stem Cell Transplant Unit which is the larger center of its kind in Africa. This hematology program mostly treats patients with blood and marrow disorders, lymph cancers and also metabolic disorders. It has equipment and facilities to rival those found anywhere else in the world. Groote Schuur Hospital (GSH) is the teaching hospital of the University of Cape Town (UCT) which first gained global fame when, in December 1967, a young UCT educated surgeon named Dr. Christiaan Barnard completed the successful human heart transplant. GSH has a Clinical Hematology Division that provides comprehensive services to patients with blood disorders, including hematological malignancies. There is an active bone marrow transplant program, which is a national referral center. The study is an open-label, multiple-dose, dose-escalation study, which is evaluating the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma, mantle cell (MCL) or diffuse large B-cell lymphoma (DLBCL) patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein in multiple myeloma and CT imaging in MCL and DLBC.

Senesco Technologies, Inc. Pays Off Line of Credit

Senesco Technologies Inc. announced that is has paid in full and canceled the line of credit held by JMP Securities. In 2010, the company opened a $3,000,000 line of credit with JMP Securities and had drawn down approximately $2,200,000.

Senesco Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2013

Senesco Technologies Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2013. For the quarter, the company reported loss from operations of $1,588,907 against $1,300,047 a year ago. Net loss was $1,619,638 against $1,269,885 a year ago. Loss applicable to common shares was $1,640,255 or $0.48 per basic and diluted share against $1,293,871 or $1.11 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $3,341,636 against $2,546,200 a year ago. Net loss was $3,403,971 against $3,355,339 a year ago. Loss applicable to common shares was $3,446,211 or $1.20 per basic and diluted share against $4,003,494 or $3.57 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNTI:US $3.30 USD -0.19

SNTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNTI.
View Industry Companies
 

Industry Analysis

SNTI

Industry Average

Valuation SNTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 120.2x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 92.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SENESCO TECHNOLOGIES INC, please visit www.senesco.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.